AzTrials
AzTrials

DyslipidemiaHDLNCT01803594

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

A study testing Krill Oil, Lutein and Nicotinic acid in people with Dyslipidemia, run by University of California, Davis at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study involves measuring subject's blood lipid responses after they consume a mixture of dietary fats of marine and dairy origin and vitamin supplements mixed into a milkshake, on three separate days. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Dyslipidemia
What is being tested?
Krill Oil, Lutein and Nicotinic acid
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
18 participants
Where
1 siteUnited States
Study dates
Aug 2012to 13 Mar 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-65 years
  • Plasma HDL cholesterol (Less than 50 mg/dL)

Who cannot join

  • History of gastrointestinal disorders like Crohns disease, colitis, irritable bowel syndrome
  • History of cardiovascular events: stroke, heart attack, cardiac arrhythmia
  • History of peptic ulcers, gastritis
  • History of gout
  • History of being under care of any psychiatric conditions (schizophrenia and depression associated with response to niacin)
  • Cancer
Show all 26Show fewer
  • Type 1 or 2 diabetes
  • Known presence of significant metabolic disease which could impact results of study (hepatic, renal disease)
  • Low blood pressure (defined as 3 consecutive readings below 100/60 mmHg at screening)
  • Self report skin sensitivities; self report to rash easily
  • Self report to hot flashes currently experience due to menopause
  • Hypersensitivity to niacin
  • Muscle disorders such as myasthenia gravis
  • Pending surgery within the next 3 months
  • Known allergy to study food (shellfish, fish, nut, soy)
  • Known intolerance to study food (lactose intolerance)
  • More than 1 serving of fish per week
  • Intake of anti-inflammatory supplemental fish, krill, borage, flax, and primrose seed oils within the last 12 weeks
  • Intake of dietary supplements consisting of concentrated soy isoflavones, resveratrol, other dietary polyphenols identified as modulators of lipids within the last 12 weeks
  • Intake of more than 20 mg of lutein and zeaxanthin per week
  • Intake of nicotinic acid (niacin) within the last 12 weeks
  • Intake of anti-coagulants, blood pressure or heart medications within the last 12 weeks
  • Plan to become pregnant in next 6 months
  • Recent initiation (past 4 weeks) of exercise program
  • Use of tobacco products
  • Excessive alcohol consumption (2 drinks/day for men and 1 drink/day for women)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UC Davis, Ragle Human Nutrition Center

    Davis, California, 95616

Other trials in United States

About this study

Official title: Postprandial Modulation of HDL Metabolism

This study involves measuring subject's blood lipid responses after they consume a mixture of dietary fats of marine and dairy origin and vitamin supplements mixed into a milkshake, on three separate days. The investigators hope to learn more about how different food ingredients influence the metabolism HDL in individuals with low blood levels of HDL cholesterol.

Read the detailed description

This study a partial randomized crossover study designed to determine how consumption of bioactive dietary ingredients in various combinations on three separate test days influences postprandial lipoprotein metabolism in participants with low circulating HDL-cholesterol.

The dietary ingredients include:

Dairy phospholipids(PC700); krill oil (K); lutein (L); and Niacin

Eligible participants will arrive to the University of California Davis (UC Davis), Ragle Human Nutrition Center on the morning of each test day after a 10-12-hr overnight fast. Upon arrival participants will fill out a questionnaire about their dietary and medication intakes and physical activity for the past 72 hours to ensure compliance. Compliant participants' weight and blood pressure will be measured and a fasting blood draw will be taken before participants consume their test meal in the form of a milkshake (control, PC700KL, PC700KL + Niacin). On each test day, participants will be given only this meal and provided with ample supply of bottled water.

Participants will only consume this test meal and water freely for the duration of the test day. Blood will be drawn serially at 2 and 4 hours postprandially. Participants will also be asked to provide 3 urine samples throughout the study: before and 2, and 4 hours after consumption of the milkshake. Participants will be tested on two additional separate test days after the first day separated by a two-week washout. The first two test days will be randomized, however the third test day will always contain niacin in order to require participants remain at Ragle for the first two hours of the study to monitor niacin flushing reactions. Participants have the option of participating in two out of three of the test days if they wish to exclude themselves from the niacin test day.

Conditions
Dyslipidemia
Being tested
Krill Oil, Lutein, Nicotinic acid, Dairy phospholipids, Control
Medical subject headings
Dyslipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Krill OilDietary supplement

    Neptune Krill Oil Gold

  • LuteinDietary supplement

    Jarrow Formulas

  • Nicotinic acidDietary supplement

    Natures Way

  • Dairy phospholipidsDietary supplement

    PC700 manufactured by Fonterra

  • ControlOther

    Control shake without dietary supplements

Study groups in NCT01803594
Study groupRoleWhat they receive
Control ShakePlacebo comparatorEach shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
Receives: Other: Control
PC700, Krill Oil, and LuteinActive comparatorEach shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)
Receives: Dietary Supplement: Krill Oil; Dietary Supplement: Lutein; Dietary Supplement: Dairy phospholipids
PC700, Krill Oil, Lutein, and NiacinActive comparatorEach shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight. Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)
Receives: Dietary Supplement: Krill Oil; Dietary Supplement: Lutein; Dietary Supplement: Nicotinic acid; Dietary Supplement: Dairy phospholipids

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma lipoprotein profile

    Plasma lipoprotein size distribution and concentration will be measured by nuclear magnetic resonance (NMR)

    Measured: 0, 2, 4 hour postprandial

Secondary outcomes (3)
  1. Plasma HDL proteome

    HDL particles isolated by ultracentrifugation will be characterized for their proteomics profile measured by mass spectrometry.

    Measured: 0, 2, 4 hours postprandial

  2. Urinary metabolomics

    Urinary metabolites will be measured by NMR spectroscopy.

    Measured: 0, 2, 4 hours

  3. Red blood cell functionality

    Red blood cells isolated from whole blood will be measured for sheer stress using an in-vitro microfluidic assay.

    Measured: 0, 2, 4 hours postprandially

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2013 (estimated)
  2. Study startAug 2012
  3. Primary completion2 Jan 2013
  4. Study completion13 Mar 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01803594
Sponsor's protocol ID
264254
Acronym
HDL
Status last verified
Sep 2022
First submitted
28 Feb 2013
Last updated
30 Sep 2022
Results posted
No
Data monitoring committee
No

Publications

  • Dalbeth N, Gracey E, Pool B, Callon K, McQueen FM, Cornish J, MacGibbon A, Palmano K. Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Ann Rheum Dis. 2010 Apr;69(4):766-9. doi: 10.1136/ard.2009.113290. Epub 2009 Aug 26.

    PubMed 19713204
  • Snow DR, Ward RE, Olsen A, Jimenez-Flores R, Hintze KJ. Membrane-rich milk fat diet provides protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. J Dairy Sci. 2011 May;94(5):2201-12. doi: 10.3168/jds.2010-3886.

    PubMed 21524510
  • Mozaffarian D, Rimm EB, Herrington DM. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. Am J Clin Nutr. 2004 Nov;80(5):1175-84. doi: 10.1093/ajcn/80.5.1175.

    PubMed 15531663
  • Tholstrup T, Vessby B, Sandstrom B. Difference in effect of myristic and stearic acid on plasma HDL cholesterol within 24 h in young men. Eur J Clin Nutr. 2003 Jun;57(6):735-42. doi: 10.1038/sj.ejcn.1601605.

    PubMed 12792657
  • Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev. 2004 Dec;9(4):420-8.

    PubMed 15656713
  • Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr. 2004 Dec;23(6 Suppl):567S-587S. doi: 10.1080/07315724.2004.10719427.

    PubMed 15640510
  • Kiokias S, Gordon MH. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress. Eur J Clin Nutr. 2003 Sep;57(9):1135-40. doi: 10.1038/sj.ejcn.1601655.

    PubMed 12947433

Questions about this trial

What is this clinical trial studying?

A study testing Krill Oil, Lutein and Nicotinic acid in people with Dyslipidemia, run by University of California, Davis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma lipoprotein profile (time frame: 0, 2, 4 hour postprandial). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01803594, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in